Special Issue "Targeting the Adenosinergic Axis in Cancer Therapy"
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: 25 January 2024 | Viewed by 236
Special Issue Editors
Interests: medicinal chemistry; rational drug design; heterocyclic compounds; structure–activity relationships; adenosine receptor ligands; carbonic anhydrase inhibitors; protein kinase CK1 and CK2 inhibitors; ecto-5'-nucleotidase (CD73) inhibitors
Special Issues, Collections and Topics in MDPI journals
Interests: medicinal chemistry; rational drug design; heterocyclic compounds; structure–activity relationships; adenosine receptor ligands; carbonic anhydrase inhibitors; protein kinase CK1 and CK2 inhibitors; ecto-5'-nucleotidase (CD73) inhibitors
Special Issues, Collections and Topics in MDPI journals
Interests: medicinal chemistry; rational drug design; heterocyclic compounds; structure–activity relationships; adenosine receptor ligands; carbonic anhydrase inhibitors; protein kinase CK1 and CK2 inhibitors; ecto-5'-nucleotidase (CD73) inhibitors
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer is a multifaceted disease with a high social impact. In fact, there are many different types of cancer, which arise in different organs, each requiring specific pharmacological approaches. The greatest barrier in cancer therapy is tumor hypoxia, which can be considered the main regulator of the adenosinergic axis. Indeed, hypoxia exerts the up-regulation of both CD73 and CD39 expression, the two enzymes that are involved in the generation of adenosine from ATP/ADP, and of adenosine receptors (ARs). The low oxygen tension in the tumor microenvironment leads to an increase in the adenosine levels that activate ARs in immune or cancer cells. The activation of the different ARs may have opposing effects in modulating cell cycle or immunity, depending on different factors. Thus, targeting the adenosinergic axis, including its generating enzymes and receptors, may represent a key strategy for cancer therapy. Moreover, since the proper role of every component of the adenosine pathway has yet to be fully understood, the discovery of small molecules as new pharmacological tools is needed.
Authors are invited to submit original articles presenting their research in this area of investigation. The proposed topics include, but are not limited to, new AR ligands and CD39 and CD73 inhibitors, designed as chemical probes for the study of the pharmacological role of adenosine in cancer. Review articles summarizing current knowledge on these topics are also of interest.
Prof. Dr. Daniela Catarzi
Prof. Dr. Vittoria Colotta
Dr. Flavia Varano
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- adenosinergic axis
- adenosine pathway
- cancer
- adenosine receptor ligands
- adenosine receptor agonists
- adenosine receptor antagonists
- CD39 inhibitors
- CD73 inhibitors
